Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Schmid Discusses the Findings of the IMpassion130 Trial in TNBC

Peter Schmid, MD, PhD
Published: Tuesday, Oct 23, 2018



Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).

The phase III IMpassion130 trial evaluated the efficacy and safety of the PD-L1 inhibitor atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) versus nab-paclitaxel alone in treatment-naïve patients with metastatic TNBC. Findings presented at the 2018 ESMO Congress showed that the addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive disease.

The median progression-free survival in the PD-L1–positive population was 7.5 months (95% CI, 6.7-9.2) with atezolizumab plus nab-paclitaxel and 5.0 months (95% CI, 3.8-5.6) with chemotherapy (HR, 0.62; 95% CI, 0.49-0.78; P <.0001). Schmid says the addition of atezolizumab to nab-paclitaxel established a clear benefit in this population. At the time of presentation, the overall survival analysis was not statistically significant, but in the PD-L1–positive patients, there was an increase in benefit with the addition of a checkpoint inhibitor.


Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses findings from the IMpassion130 trial in triple-negative breast cancer (TNBC).

The phase III IMpassion130 trial evaluated the efficacy and safety of the PD-L1 inhibitor atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) versus nab-paclitaxel alone in treatment-naïve patients with metastatic TNBC. Findings presented at the 2018 ESMO Congress showed that the addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive disease.

The median progression-free survival in the PD-L1–positive population was 7.5 months (95% CI, 6.7-9.2) with atezolizumab plus nab-paclitaxel and 5.0 months (95% CI, 3.8-5.6) with chemotherapy (HR, 0.62; 95% CI, 0.49-0.78; P <.0001). Schmid says the addition of atezolizumab to nab-paclitaxel established a clear benefit in this population. At the time of presentation, the overall survival analysis was not statistically significant, but in the PD-L1–positive patients, there was an increase in benefit with the addition of a checkpoint inhibitor.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Miami Breast Cancer Conference®: Attendee Tumor Board OnlineNov 30, 20181.5
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
Publication Bottom Border
Border Publication
x